Tech Company Financing Transactions
FEMSelect Funding Round
FEMSelect, operating out of Newark, secured $9 million in funding from New Age Ventures, Triventures and Keiretsu Capital.
Transaction Overview
Company Name
Announced On
10/19/2022
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Series B
Investors
Proceeds Purpose
Funds Will Expand Commercialization of Company's EnPlace® Approach to Minimally Invasive Prolapse Repair.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Undisclosed
Newark, DE Undisclosed
USA
Newark, DE Undisclosed
USA
Phone
Website
Email Address
Overview
Israel-based FEMSelect® is the developer of EnPlace®, the FDA cleared and CE Marked system for suturing ligaments of the pelvic floor as an approach to minimally-invasive Pelvic Organ Prolapse (POP) procedures. The EnPlace® approach is much simpler to perform -- and much easier to recover from - than the current standard of care dissection approach.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Deborah Garner
Co-Founder
Boaz Harari
Co-Founder
Menahem Neuman
Browse more venture capital transactions:
Prev: 10/19/2022: Upheal venture capital transaction
Next: 10/19/2022: Wilkinson Baking Company venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries on this site come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs